Huben R P, Pontes J E
Int Adv Surg Oncol. 1984;7:355-72.
Despite impressive advances in the therapy of testis tumors, many controversies remain regarding the optimal therapy for each stage of disease. Primary cytoreductive chemotherapy is the treatment of choice for all advanced germ cell tumors, whether nonseminomatous or seminomatous. The distinction between seminomas and other germ cell tumors may be more historic than real. A unified staging system is desperately needed so that results of treatment modalities may be more easily compared, and the need for further multiinstitutional, randomized treatment protocols is also evident. With present treatment options, about 90% of all patients with germ cell tumors should be cured of their diseases, and aggressive efforts at early recognition and the development of newer therapies for relapsing patients are indicated. While further consideration of the long-term consequences of the various treatment modalities is necessary, any resultant modifications in treatment strategy cannot be at the expense of present cure rates.
尽管睾丸肿瘤的治疗取得了令人瞩目的进展,但对于疾病各阶段的最佳治疗方案仍存在诸多争议。原发性细胞减灭化疗是所有晚期生殖细胞肿瘤(无论是非精原细胞瘤还是精原细胞瘤)的首选治疗方法。精原细胞瘤与其他生殖细胞肿瘤之间的区别可能更多是历史性的而非实际存在的。迫切需要一个统一的分期系统,以便更轻松地比较治疗方式的结果,并且显然也需要进一步开展多机构、随机化的治疗方案。采用目前的治疗选择,所有生殖细胞肿瘤患者中约90%应能治愈其疾病,因此有必要积极努力尽早识别并为复发患者开发更新的治疗方法。虽然有必要进一步考虑各种治疗方式的长期后果,但治疗策略的任何最终调整都不能以牺牲当前的治愈率为代价。